TIGAR: An Improved Bayesian Tool for Transcriptomic Data Imputation Enhances Gene Mapping of Complex Traits

Jingjing Yang, PhD





Outline

Introduction

Methods

Transcriptome-wide Association Study Gene Expression (GReX) Imputation Models Gene-based Association Test

Results

Simulation Studies Mapping Alzheimer's Dementia Related Phenotypes

TWAS Based on SKAT

Application Results with ROS/MAP Data

Introduction

Methods

Results


TWAS Based on SKAT

Etiology of Complex Diseases


Examples complex diseases


Type II Diabetes, Cardiovascular Diseases, Alzheimer's Dementia

- Polygenic with low penetrance by individual genes
- Largely unknown genomic etiology
- Integrate multi-layers of Omics data




Overview of Genomics Data





GOAL of Mapping Complex Human Diseases



McCarthy I.M. et. al. Nature Reviews. 2008.


GWAS Findings

2018 Apr

Associations: 69,885

Studies: 5,152

Papers: 3,378





GWAS: Genome-wide Association Study

Introduction

Methods

Transcriptome-wide Association Study Gene Expression (GReX) Imputation Models Gene-based Association Test


Results

TWAS Based on SKAT

Integrate Transcriptomic Data in GWAS

Transcriptome-wide Association Study (TWAS)


- Leverage existing public transcriptomic data resources (e.g., GTEx, GEUVADIS, DGN)
- Conduct "Functional" gene-based association test
- Improve biological interpretation
- Identify novel risk genes



Gamazon ER et. al., Nat Genetics, 2015.

Existing Tools

- Predixcan: based on the Elastic-Net penalized linear regression model (EN). Gamazon et. al., Nat Genetics, 2015.
- FUSION: based on the Bayesian Sparse Linear Mixed Model (BSLMM). Gusev et. al. Nat Genetics. 2016.



Nonparametric Bayesian Model

Advantages

- Include parametric models (e.g., Elastic-Net, BSLMM) as special cases
- Better modeling the underlying complex genetic architecture of transcriptomic profiles
- Improve GReX imputation accuracy
- Improve TWAS power

Nonparametric Bayesian Model

- Considering gene expression levels \mathbf{E}_g of gene g genotype data matrix $\mathbf{X}_{n \times p}$ of all cis-SNPs
- E_g are normalized and adjusted for confounding covariates such as age, sex, top genotype PCs, PEER factors of transcriptomic data
- The nonparametric Bayesian Dirichlet process regression (DPR) model (Zeng & Zhou, Nat. Comm., 2017) is setup as:

$$\mathbf{E_g} = \mathbf{X_{n \times p} w_{p \times 1}} + \boldsymbol{\varepsilon}, \ \boldsymbol{\varepsilon} \sim N(0, \sigma_{\varepsilon}^2 \mathbf{I}), \ \sigma_{\varepsilon}^2 \sim IG(a_{\varepsilon}, b_{\varepsilon})$$

$$w_i \sim N(0, \sigma_{\varepsilon}^2 \sigma_w^2), \ \sigma_w^2 \sim D, \ D \sim DP(IG(a, b), \xi), \ i = 1, \cdots, p$$

• Estimate cis-eQTL effect-sizes $\mathbf{w}_{p \times 1}$ by MCMC or Variational Bayesian Approximation

Nonparametric Bayesian Model

Another intuitive way of viewing this nonparametric model

- σ_w^2 can be viewed as a Latent variable
- Integrating out σ²_w will induce a Nonparametric prior distribution on w_i
- Equivalent to a normal mixture model for w_i

$$w_{i} \sim \pi_{0}N(0, \sigma_{\varepsilon}^{2}\sigma_{0}^{2}) + \sum_{k=1}^{+\infty} \pi_{k}N(0, \sigma_{\varepsilon}^{2}(\sigma_{k}^{2} + \sigma_{0}^{2}));$$

$$\pi_{k} = v_{k} \prod_{l=0}^{k-1} (1 - v_{l}), \ v_{k} \sim Beta(1, \xi), \ \xi \sim Gamma(a_{\xi}, b_{\xi});$$

$$\sigma_{k}^{2} \sim IG(a_{k}, b_{k}), \ k = 0, 1, \dots, +\infty.$$

Gene-based Association Test by Existing TWAS Tools

General framework with phenotype Y, genotype matrix X, and covariate matrix Z

$$g(E[Y|X,Z]) = \beta \widehat{GReX} + Z\alpha,$$

$$\widehat{GReX} = X\hat{w}$$

$$H_0: \boldsymbol{\beta} = 0$$

Equivalent to a gene-based burden test taking cis-eQTL effect size estimates $\hat{\mathbf{w}}$ as variant weights

Introduction

Methods

Results

Simulation Studies Mapping Alzheimer's Dementia Related Phenotypes

TWAS Based on SKAT

Simulation Study Design

- Use the real genotype data of gene ABCA7 with 2,799
 cis-SNPs with MAF > 5% and HWP > 10⁻⁵
- Training sample size (100,300,499), test sample size 1,200
- Consider scenarios with various proportion of causal SNPs for gene expression, $p_{causal} = (0.01, 0.05, 0.1, 0.2)$
- Consider scenarios with various gene expression heritability and phenotype heritability, $(p_e^2, p_h^2) = ((0.05, 0.8), (0.1, 0.5), (0.2, 0.25), (0.5, 0.1))$
- Compare PrediXcan and DPR methods with respect to gene expression prediction R² and TWAS power




Figure 1: Gene expression prediction R^2 on test data.




Figure 2: TWAS power with test data.





Figure 3: Gene expression prediction R^2 and TWAS power with various sample sizes.

ROS/MAP Data

- Prospective cohort studies of aging and dementia with participants of Religious Orders Study (ROS) and Rush Memory and Aging Project (MAP)
- GWAS data of 2,093 European samples
- RNAseq data (transcriptomic profiles) of 499 post-mortem brain samples that also have GWAS genotype data (after QC)
- Considered two important indices of Alzheimer's dementia pathology as quantitative complex traits
 - β-amyloid (Amyloid)
 - Neurofibrillary tangle density (Tangles)

PrediXcan vs. DPR



TWAS of Amyloid by DPR




Figure 4: TWAS of β -Amyloid using DPR weights.

TWAS of Tangles by DPR




Figure 5: TWAS of Tangles using DPR weights.

Multiphenotype TWAS by DPR





Figure 6: Multiphenotype TWAS with β -Amyloid and Tangles using DPR weights.

TWAS Results with GWAS Summary Statistics

TWAS of known AD loci using DPR weights estimated from ROS/MAP data and public GWAS summary statistics by IGAP



Introduction

Methods

Results

TWAS Based on SKAT
Application Results with ROS/MAP Data

SKAT TWAS

Sequencial Kernel Association Test (SKAT) (Wu et. al. AJHG, 2011)

 General framework with phenotype Y, genotype matrix X, and covariate matrix Z

$$g(E[Y|X,Z]) = \boldsymbol{\beta'}X + \boldsymbol{\alpha'}Z, \ \beta_i \sim N(0, w_i^2 \tau)$$

- $H_0: \tau = 0$
- Variance-component score statistic with a diagonal weight matrix W and phenotype mean $\hat{\mu}$ estimated under H_0

$$Q = (y - \hat{\mu})'K(y - \hat{\mu}), K = XWX'$$

- TWAS: use cis-eQTL effect size estimates $\hat{w_i}$ by DPR method as variant weights, $W_{i,i} = \hat{w_i}^2$
- Q follows a mixture chi-square distribution under H₀




Figure 7: SKAT TWAS with β -Amyloid.




Figure 8: SKAT TWAS with Tangles.

Introduction

Methods

Results

TWAS Based on SKAT

- Nonparametric Bayesian method is preferred when the proportion of causal SNPs > 0.01 or expression heritability < 0.2
- TWAS results can help interpret significant risk gene loci
- Promising TWAS results in ROS/MAP application studies by using nonparametric Bayesian method
 - Potentially novel loci TRAPPC6A, ZNF234, HSPBAP1 for AD pathological indexes
 - Known AD loci ADAM10, CD2AP, TREM2 identified by TWAS
- Multiple phenotype TWAS can leverage pleiotropy

Published Paper



Software Resource

Transcriptome-Integrated Genetic Association Resource https://github.com/yanglab-emory/TIGAR

- Implement both Elastic-Net and DPR models for training GReX imputation models
- Integrate training GReX imputation model, GReX prediction, TWAS in the same tool
- TWAS based on Burden test and SKAT
- TWAS with both individual-level and summary-level GWAS data
- TWAS with multiple phenotypes
- Multi-thread computation
- Load VCF/Dosage genotype input files

Acknowledgement

Yang Lab

github.com/
yanglab-emory



Rush Alzheimer's Disease Center www.radc.rush.edu



